Navigation Links
The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Date:10/9/2007

his partnership is that it breaks down barriers often associated with clinical trial participation," said John Sweetenham, M.D., Taussig's director of clinical research. "The strides made under this partnership will accelerate the process of developing and delivering new, more advanced drugs for patients and will allow us to bring these needed treatments out to people in their own communities without them having to travel downtown."

While most national clinical trials are conducted by cooperative groups -- vast networks of physicians, researchers, medical centers and universities across the country -- the Society-backed Cleveland Clinic program will greatly streamline the process and expedite the advancement of new drugs, since the trials will all be conducted by a single clinical center. The partnership aims to undertake more than six clinical trials over the next three years, enrolling 100 to 150 patients, increasing the number of trials typically completed for these types of cancers in this timeframe.

The Society, which has set as one of its strategic goals the acceleration of blood cancer therapies by enrolling more people in clinical trials, has access to new therapies and will help determine which drugs should be tested.

The Taussig Cancer Institute will help design the trials and administer them. The organizations will co-fund the effort.

"Bureaucracy is the silent killer in cancer," said Dr. DeGennaro. "This partnership will enable us to address many of the serious bottlenecks that delay the development of new therapies for blood cancer patients. Our ultimate goal is to get new treatments to patients faster and save more lives."

After the three-year pilot, future plans for the program include potentially extending it to the National Cancer Institute Case Comprehensive Cancer Center, in which both Taussig and the Ireland Cancer Center partner.

For more information about The Clinical Trial Center for Hematologic Malignancies
'/>"/>

SOURCE Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
2. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
3. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Major Gene Study Uncovers Secrets of Leukemia
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
10. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
11. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Calif. , July 31, 2014  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Access Conference, New York, NY Wednesday, ... Baird Health Care Conference, New York, NY ... Time , Accessing Live Webcasts To access the ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... 31, 2014 Dr. Stewart Shofner ... the first surgeons in the United States to successfully treat ... the smallest medical device ever approved by the FDA. ... recognize the benefits of using a procedure known as Selective ... Shofner and his colleagues now recognize that this procedure is ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... marketing expert Adam Short that is designed to provide a ... has caught the attention of Shane Michaels, prompting an investigative ... here . , “What really speaks volumes about the success ... the tactics and strategies included in it have stayed effective ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:United Theological Seminary to Open 144th Year 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... RICHMOND, Va., April 29 The principal U.S. investigator,for ... for,malpractice in his use of the device by a ... No. 07-206, Circuit Court, City of Richmond, Va., ... H.,Mathews, M.D., and Midatlantic Spine Specialists, P.C. Dr. Mathews ...
... 1950 had agreement on standard outcomes, review finds , , ... the appropriate measurements for assessing drug clinical trials that ... 9,000 pediatric clinical trials conducted since 1950. , They ... none have involved children in the process to select ...
... PITTSBURGH, April 29 Mylan Inc. (NYSE: MYL ... approval,from the U.S. Food and Drug Administration (FDA) for ... mg, 2 mg and 4 mg., Trandolapril Tablets ... and generic versions of this product had total U.S.,sales ...
... A New LTCI Presentation System Designed for Today,s ... LLC, the leader in,providing long-term care insurance sales, ... announced the release of,simplifyingLTC, a LTCI presentation system ... presentation system communicates the risk of long-term care ...
... More than 50,000 doctors,have given 20 million free ... to Reach Out and Read. Partnering with doctors ... to their parents at check-ups, Reach,Out and Read ... toddlers,and preschoolers. The children,s literacy program recently reached ...
... Growth of 27-29 Percent over ... 2007 First-Quarter Year-Over-Year Highlights (adjusted for January 2008 ... two-for-one stock split): - GAAP ... from $0.52, excluding $0.05 in amortization of intangible assets ...
Cached Medicine News:Health News:Virginia Judge Rules Medical Device Pioneer Committed Malpractice 2Health News:Measurements Poor for Assessing Clinical Trials With Children 2Health News:SellingLTC.com Develops simplifyingLTC 2Health News:20 Million Kids' Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 3Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 4Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 5Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 6Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 7Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 8Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 9Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 10Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 11Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 12Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 13Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 14Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 15Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 16Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 17Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 18Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 19Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 20Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 21Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 22Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 23Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 24Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 25
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... musculofascial tract, renal capsule, and parenchyma during ... the catheter shaft. Radiopaque markers are placed ... the balloon. The radiopaque dilator/sheath assembly is ... coaxial placement of the sheath. Supplied sterile ...
... Therapy for Urinary Control offers a ... and the symptoms of overactive bladder, ... symptoms of urgency-frequency alone or in ... or could not tolerate more conservative ...
... Receiving timely, high-quality and accurate,ECG ... care. The,Quinton Eclipse Premier allows ... test results,and make a diagnosis ... sharing capabilities.,Workload is further streamlined ...
Medicine Products: